Axon Enterprise (NASDAQ:AXON) Given New $525.00 Price Target at Needham & Company LLC

Axon Enterprise (NASDAQ:AXON) had its price target upped by Needham & Company LLC from $400.00 to $525.00 in a report issued on Tuesday, Benzinga reports. Needham & Company LLC currently has a buy rating on the biotechnology company’s stock.

Several other research firms have also weighed in on AXON. Bank of America began coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $380.00 target price for the company. JMP Securities lifted their target price on shares of Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Jefferies Financial Group started coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price target on the stock. Robert W. Baird boosted their price target on shares of Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Finally, Craig Hallum upped their target price on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $382.85.

Axon Enterprise Trading Up 0.3 %

AXON stock opened at $444.52 on Tuesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The company has a market capitalization of $33.55 billion, a PE ratio of 129.98, a P/E/G ratio of 12.05 and a beta of 0.94. The firm’s 50-day moving average is $396.09 and its 200 day moving average is $336.34. Axon Enterprise has a 12 month low of $199.29 and a 12 month high of $455.17.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. During the same period last year, the business earned $0.80 EPS. Axon Enterprise’s revenue for the quarter was up 34.5% on a year-over-year basis. On average, research analysts anticipate that Axon Enterprise will post 1.79 EPS for the current year.

Insiders Place Their Bets

In other news, President Joshua Isner sold 25,811 shares of Axon Enterprise stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $359.84, for a total transaction of $9,287,830.24. Following the completion of the transaction, the president now owns 228,166 shares of the company’s stock, valued at $82,103,253.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Axon Enterprise news, President Joshua Isner sold 25,811 shares of Axon Enterprise stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $359.84, for a total value of $9,287,830.24. Following the completion of the sale, the president now owns 228,166 shares in the company, valued at $82,103,253.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Matthew R. Mcbrady sold 2,000 shares of the business’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $364.66, for a total value of $729,320.00. Following the sale, the director now owns 4,892 shares of the company’s stock, valued at $1,783,916.72. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 371,172 shares of company stock worth $137,000,162. 6.10% of the stock is owned by corporate insiders.

Institutional Trading of Axon Enterprise

Several institutional investors have recently added to or reduced their stakes in AXON. Motley Fool Asset Management LLC raised its position in shares of Axon Enterprise by 238.7% during the 1st quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock worth $153,981,000 after purchasing an additional 346,838 shares during the period. 1832 Asset Management L.P. bought a new stake in shares of Axon Enterprise during the 1st quarter worth $81,630,000. International Assets Investment Management LLC acquired a new stake in shares of Axon Enterprise in the third quarter worth $871,860,000. Vanguard Group Inc. boosted its position in shares of Axon Enterprise by 2.7% in the first quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock worth $2,547,878,000 after buying an additional 212,401 shares during the period. Finally, Swedbank AB acquired a new stake in shares of Axon Enterprise in the first quarter worth $39,923,000. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.